| Company Name: |
TargetMol
|
| Tel: |
400-821-0310 15002144251 |
| Email: |
xuexiang.shao@tsbiochem.com |
| Products Intro: |
Product Name:LETC
CAS:951131-13-8
Package:10mg;50mg
|
|
| | 10H-Phenothiazine-3,7-diamine, N3,N3,N7,N7-tetraethyl-, hydrochloride (1:2) Basic information |
| Product Name: | 10H-Phenothiazine-3,7-diamine, N3,N3,N7,N7-tetraethyl-, hydrochloride (1:2) | | Synonyms: | 10H-Phenothiazine-3,7-diamine, N3,N3,N7,N7-tetraethyl-, hydrochloride (1:2);LETC | | CAS: | 951131-13-8 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![10H-Phenothiazine-3,7-diamine, N3,N3,N7,N7-tetraethyl-, hydrochloride (1:2) Structure]() |
| | 10H-Phenothiazine-3,7-diamine, N3,N3,N7,N7-tetraethyl-, hydrochloride (1:2) Chemical Properties |
| form | Solid | | color | Light blue to blue |
| | 10H-Phenothiazine-3,7-diamine, N3,N3,N7,N7-tetraethyl-, hydrochloride (1:2) Usage And Synthesis |
| Uses | LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC50 of 66 nM in transfected DH60.21 neuroblastoma cells. LETC can cross the blood-brain barrier. LETC can be used for the study of synucleinopathies[1]. | | in vivo | LETC (10 mg/kg; po; for 5 days per week; for 6 weeks) significantly decreases α-Syn-positive neurons in multiple brain regions and this resulted in a rescue of movement deficits in the open field in these mice. LETC does not improve activity deficits of L62 mice in the home cage environment[1].
In α-Syn transgenic L62 mice, LETC accumulated in the brain with a half-life of about 6 h after oral administration[1].
Pharmacokinetic parameters obtained in L62 mice after a single oral dose of LETC (15 mg/kg).
1.19 | parameter | Plasma | Brain | | Cmax (ng/mL) | 155.0 | 1013.5 | | Tmax (h) | 1.0 | 1.0 |
| Animal Model: | Full-length human α-Syn overexpressing Line 62 (L62) mice mice[1] | | Dosage: | 10 mg/kg | | Administration: | Oral gavage; for 5 days per week; for 6 weeks | | Result: | Significantly decreased α-Syn-positive neurons in multiple brain regions. |
| | IC 50 | α-synuclein Aggregation | | References | [1] Karima Schwab, et al. LETC inhibits α-Syn aggregation and ameliorates motor deficiencies in the L62 mouse model of synucleinopathy. Eur J Pharmacol. 2024 May 5:970:176505. DOI:10.1016/j.ejphar.2024.176505 |
| | 10H-Phenothiazine-3,7-diamine, N3,N3,N7,N7-tetraethyl-, hydrochloride (1:2) Preparation Products And Raw materials |
|